Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Appoints New Chief Executive After Months of Speculation - WSJ
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
FDA approves first rival generic EpiPen, sending Teva shares up 6% - MarketWatch
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva to lay off 14,000 workers in bid for survival — but some are skeptical - MarketWatch
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Pharmaceuticals - Wikipedia
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Teva shares surge on corporate shake-up - MarketWatch
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
Perrigo rejects Mylan, opening door for Teva - MarketWatch
Teva Pharmaceutical Is in Recovery - WSJ
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva Pharmaceutical CEO Talks Opioids, Lawsuits, and the Long Road Ahead | Barron's
Bulk of earnings pressure in the first half of 2023, says Citi's Scott Chronert
MarketWatch on Twitter: "Teva Pharmaceutical named Kare Schultz as its new chief executive https://t.co/pyLR2vL5Ep https://t.co/pD8godrT5C" / Twitter
